High-purity therapeutic and research-grade sequences manufactured under rigid ISO 9001 and cGMP-compliant standards, backed by full multi-ton synthesis capabilities.
A deep biochemical analysis of the 28-amino acid pleiotropic peptide responsible for profound immune modulation, dendritic cell stimulation, and epigenetic toll-like receptor signaling.
Thymosin alpha 1 (Ta1) is an acidic 28-amino acid peptide derived from the native prothymosin alpha precursor. Its sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. With an acetylated N-terminus and an exceptionally high concentration of dicarboxylic amino acid residues (Glu and Asp), industrial scale production requires strict preservation of chiral fidelity.
Unlike blunt-force immunosuppressive or immunostimulatory agents, Ta1 acts as an endogenous systemic balance modulator. By binding Toll-Like Receptors (TLR-2, TLR-9, and TLR-7) on myeloid and plasmacytoid dendritic cells, it stimulates the maturation of naive CD4+/CD8+ T cells, enhances natural killer (NK) cell cytotoxicity, and simultaneously drives regulatory T-cell (Treg) differentiation to mitigate hyper-inflammatory cytokine cascades.
With an exact empirical formula of C129H215N33O45 and a monoisotopic molecular weight of 3108.3 Da, Ta1 displays high solubility in aqueous buffer matrices across neutral and slightly basic pH ranges. However, its multiple internal aspartyl and glutamyl sequences make it prone to beta-sheet aggregation, aspartimide formation, and acid-catalyzed deamidation if cleavage conditions are suboptimal.
Strategic analysis of the shifting global market for immunogenic peptide APIs, regulatory barriers, and modern CDMO industrialization challenges.
The global demand for Thymosin Alpha-1 has surged exponentially across oncology, post-viral convalescence, and vaccine adjuvant formulation pipelines. Historically, global supply was restricted by low-yield native extraction and small-batch classical synthesis. Today, leading Chinese manufacturing hubs like Thinheal have engineered integrated multi-ton automated microwave-assisted Solid-Phase Peptide Synthesis (SPPS) paradigms. This provides Western, Asian, and Latin American biopharma partners with consistent material flow free from raw material bottlenecks and trade volatility.
Industrial scale-up of Ta1 encounters severe hurdles: sequential elongation yield loss, aspartimide ring closure at Asp-Gly/Asp-Leu junctions, and high downstream purification overhead due to closely migrating (des-Ala) and (des-Ser) deletion artifacts. Modern enterprise CDMO solutions integrate continuous flow synthesis, green chemistry solvent recovery (recycling DMF/NMP), and multi-stage axial preparative HPLC. These systems ensure cost efficiency without compromising regulatory conformance.
Standard pricing schedules for cGMP and pre-clinical contract manufacturing. Tiered pricing varies according to required counter-ion formulation, lot release assays, and regulatory documentation packages.
| Grade / Specification Tier | Target Purity (HPLC) | Endotoxin Profile | Standard Batch Scale | Indicative Price Range | Regulatory File Deliverables |
|---|---|---|---|---|---|
| Pre-Clinical / Discovery | ≥95.0% - 98.0% | ≤10 EU/mg | 10g – 500g | $140 – $220 / gram | Standard CoA, RP-HPLC, ESI-MS Identification |
| Pilot / Toxicology Stage | ≥98.0% | ≤2.0 EU/mg | 500g – 2.5 kg | $95 – $150 / gram | CoA, LC-MS/MS Impurity Profile, Residual Solvents |
| Commercial Generic cGMP API | ≥99.0% (Single Imp <0.5%) | ≤0.1 EU/mg (Aseptic) | 5 kg – 50 kg | $45 – $85 / gram | Full DMF (Type II / CEP), Stability (ICH Q1A), Process Validation |
| Lyophilized Finished Vials | 1.6mg / vial (Active Base) | <0.05 EU/vial (Sterile) | 10,000 – 100,000 vials | $1.80 – $3.50 / vial | Batch Release Records, Sterility Assurance, Container-Closure Validation |
Pricing must account for net peptide content (NPC). Standard lyophilized raw bulk carries acetate and moisture weight, usually delivering 80-85% NPC. Thinheal calculates cost per actual active peptide milligram to guarantee exact finished dosage calculation for fill-finish facilities.
While standard research batches employ Trifluoroacetic Acid (TFA) salts, regulatory finished therapeutics require complete conversion to acetate, chloride, or sodium salt matrices. Thinheal's validated ion-exchange resins achieve residual TFA levels below 0.05%, exceeding USP/EP guidelines.
Long-term generic commercial supply programs feature index-linked raw material price collars and committed reserve safety inventory. We provide dedicated cleanroom bays and recurring production campaigns with fixed price locks for 12 to 36-month cycles.
Eliminating cross-border technical hurdles through specialized regulatory desks, full dossier generation, and compliant temperature-controlled cold chains.
We supply complete Common Technical Document (CTD) Module 3 quality sections, including detailed synthetic route validation, starting material controls, impurity clearing audits, and analytical method re-validation data packages.
All batches undergo accelerated and real-time stability protocols compliant with ICH Q1A guidelines (25°C/60% RH, 40°C/75% RH, and -20°C deep freeze) in pharmaceutical-grade stability chambers with dual power redundancy.
International air shipments run on validated passive and active dry-ice or +2°C to +8°C temperature logging pods. Integrated cellular IoT dataloggers provide end-to-end GPS, temperature, and customs status tracking.
Our multilingual account managers provide native-language support across North America, the European Union, the CIS region, and Asia-Pacific, quickly addressing regulatory clarifications and customer audits.
Real-world implementation frameworks for bulk Thymosin Alpha-1 across major pharmaceutical and clinical pipelines.
Ta1 is widely formulated alongside standard checkpoint inhibitors (anti-PD-1, anti-CTLA-4) and post-chemotherapy interventions. By preventing chemotherapy-induced lymphopenia and stimulating CD8+ T-cell infiltration within "cold" tumors, it serves as a critical active pharmaceutical ingredient in immuno-oncology protocols.
Extensively deployed throughout Asia, Southern Europe, and Latin America for Hepatitis B and C treatment paradigms. In combination with nucleoside analogues or pegylated interferons, Ta1 drives sustained virological response (SVR) and preserves hepatic architecture from fibrotic degeneration.
In acute critical-care medicine, severe sepsis frequently induces secondary immune paralysis marked by anergy and mass T-cell apoptosis. Infusion protocols using high-purity, endotoxin-free Ta1 restore human leukocyte antigen-DR (HLA-DR) expression on monocytes, significantly reducing ICU mortality rates.
Next-generation chemical synthesis methods designed to lower environmental impact, reduce crude impurity profiles, and increase synthetic yield.
Thinheal is transitioning from pure linear Solid-Phase synthesis to hybrid Liquid-Phase/Solid-Phase Segment Condensation (LPOS). By synthesizing protected pentapeptide segments and performing liquid-phase coupling, overall synthesis time is reduced by 40% while eliminating trace deletion sequences that are challenging to separate chromatographically.
Traditional SPPS generates substantial hazardous organic waste, primarily dimethylformamide (DMF) and dichloromethane (DCM). Thinheal is validating non-toxic bio-based solvents, such as Cyrene and 2-MeTHF, along with automated real-time PAT (Process Analytical Technology) UV-monitoring for coupling completion, cutting total solvent consumption by over 50%.
Native Ta1 has an in vivo plasma elimination half-life of roughly two hours, requiring frequent subcutaneous dosing. In collaboration with university research groups, our CDMO labs are testing mono-PEGylated variants, lipid-conjugated motifs, and SNAC-based oral encapsulation systems to prolong circulation time without compromising receptor-binding kinetics.
Key technical specifications, analytical release standards, and batch logistics for procurement teams evaluating custom Ta1 peptide lots.
The sequence of Thymosin Alpha-1 contains several sensitive aspartic acid residues (e.g., Asp-Leu, Asp-Thr). During repetitive piperidine deprotection cycles, these motifs are prone to alpha-to-beta aspartyl shifting via cyclic aspartimide intermediates. Thinheal utilizes sterically hindered protecting groups (such as Asp(OtBu) and Asp(OMpe)) combined with the addition of 0.1 M HOBt or formic acid to the piperidine solutions, suppressing aspartimide formation to below 0.05% in the crude peptide.
Every commercial batch is supplied with an extensive Certificate of Analysis containing: RP-HPLC (purity and related substances profile), High-Resolution ESI-MS or MALDI-TOF (molecular weight confirmation), Peptide Content Analysis (elemental nitrogen or amino acid analysis), Karl Fischer titration (water content <5.0%), Acetic Acid content (ion chromatography), Residual Trifluoroacetic Acid (<0.1% or non-detectable), Residual Solvents (GC-HS per ICH Q3C), Bacterial Endotoxins (kinetic turbidimetric or chromogenic LAL testing), and Bioburden (total viable aerobic count).
Research grade Ta1 is intended for in vitro assays, high-throughput screening, and non-GLP laboratory work. It confirms basic sequence accuracy and purity (typically ≥95-98%), but may retain trace trifluoroacetate ions and higher bioburden limits. Commercial cGMP API is produced in Class 100,000 / ISO 8 cleanroom suites with validated cleaning procedures, qualified HVAC systems, full batch production records, strict environmental monitoring, sub-ambient cold-chain holding validation, complete impurity qualification, and regulatory DMF availability for submission to global health authorities.
Yes. Beyond supplying bulk crystalline/lyophilized powder in fluoropolymer-lined containers, our aseptic fill-finish suites can produce finished, sterile lyophilized vials containing custom bulking excipients (e.g., mannitol, trehalose, sodium chloride) under specific reconstitution pH requirements. Standard configurations include 1.6 mg, 3.2 mg, and 5.0 mg active base vials with custom labeling, crimping, and serialization for direct clinical or commercial use.
Standard catalog and pilot quantities (10g to 1kg) are typically dispatched from stock within 3-5 business days. Custom contract synthesis orders ranging from 5kg to 50kg require 4 to 8 weeks, including complete analytical release testing and stability staging. All shipments are packaged in validated vacuum-sealed, light-protective glass or HDPE bottles packed inside insulated temperature-controlled cold boxes with certified dataloggers, maintaining product integrity throughout customs clearance.
Explore additional high-demand APIs produced in our multi-ton facility. Full technical dossiers, batch pricing, and COAs are available on request.
Partner with Hangzhou Thinheal Pharma-Tech Co., Ltd. for reliable peptide API supply, CDMO synthesis, and regulatory documentation. Contact our regional sales engineering desks today.
Thin
